Home » Stocks » VBLT

Vascular Biogenics Ltd. (VBLT)

Stock Price: $2.63 USD -0.09 (-3.31%)
Updated Jan 27, 2021 12:02 PM EST - Market open
Market Cap 131.07M
Revenue (ttm) 843,000
Net Income (ttm) -22.70M
Shares Out 47.90M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $2.63
Previous Close $2.72
Change ($) -0.09
Change (%) -3.31%
Day's Open 2.81
Day's Range 2.51 - 2.81
Day's Volume 358,451
52-Week Range 0.96 - 2.91

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

Agreement extends current cash runway to Q1 2023 Agreement extends current cash runway to Q1 2023

GlobeNewsWire - 4 weeks ago

TEL AVIV, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the expansion of its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111...

GlobeNewsWire - 1 month ago

TEL AVIV, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first...

Seeking Alpha - 2 months ago

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 28.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the...

Benzinga - 2 months ago

Shares of Vascular Biogenics (NASDAQ:VBLT) moved higher by 0.8% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 14.29% year over year ...

GlobeNewsWire - 2 months ago

- Continued progress in OVAL Phase 3 potential-registration study in patients with platinum-resistant ovarian cancer; high response rates (RR) of over 50% in the total evaluable patient popula...

GlobeNewsWire - 2 months ago

TEL AVIV, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first...

GlobeNewsWire - 2 months ago

TEL AVIV, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first...

GlobeNewsWire - 3 months ago

TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it has appointed Marc Kozin as Vice Chairman of the Board. Mr. Kozin will transition to...

GlobeNewsWire - 3 months ago

TEL AVIV, Israel, Oct. 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that the European Patent Office (EPO) has granted Patent #3328408, which covers VBL’s propr...

GlobeNewsWire - 3 months ago

TEL AVIV, Israel, Sept. 29, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of fi...

GlobeNewsWire - 4 months ago

TEL AVIV, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of fi...

GlobeNewsWire - 4 months ago

TEL AVIV, Israel, Sept. 15, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will present today a corporate overview, including an update on the OVAL pivotal study, at the H. C. Wain...

GlobeNewsWire - 4 months ago

TEL AVIV, Israel, Sept. 11, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today presents for the first time new data demonstrating ex-vivo activity of its proprietary investi...

GlobeNewsWire - 4 months ago

TEL AVIV, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that the first two patients have been enrolled in the Phase 2 clinical trial of VB-111 i...

GlobeNewsWire - 4 months ago

TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today the successful completion of a Type B pre-IND meeting with the U.S. Food and Drug Adminis...

Seeking Alpha - 5 months ago

Vascular Biogenics Ltd (VBLT) CEO Dror Harats on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 0.00% and -15.05%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 5 months ago

Shares of Vascular Biogenics (NASDAQ:VBLT) decreased 9% in pre-market trading after the company reported Q2 results.

GlobeNewsWire - 5 months ago

TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that the independent Data Safety Monitoring Committee (DSMC) has completed its second, pre...

Zacks Investment Research - 5 months ago

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 5 months ago

TEL AVIV, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of fir...

GlobeNewsWire - 7 months ago

The company's bi-specific antibody candidates significantly prolonged survival in models of metastatic human cervical and breast cancer The company's bi-specific antibody candidates significan...

GlobeNewsWire - 7 months ago

TEL AVIV, Israel, June 01, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced the presentation of the positive outcome of pre-planned interim analysis results from the...

Seeking Alpha - 8 months ago

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q1 2020 Results - Earnings Call Transcript

Benzinga - 8 months ago

Shares of Vascular Biogenics (NASDAQ:VBLT) were flat in pre-market trading after the company reported Q1 results.

Zacks Investment Research - 8 months ago

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 6.25% and 89.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 8 months ago

Conference Call and Webcast at 8:30am Eastern Time Today Conference Call and Webcast at 8:30am Eastern Time Today

GlobeNewsWire - 8 months ago

Raised $18.1 Million of Gross Proceeds in Two Registered Direct Offerings Raised $18.1 Million of Gross Proceeds in Two Registered Direct Offerings

GlobeNewsWire - 8 months ago

TEL AVIV, Israel, May 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced registered direct offering of 6,349,208 ordina...

Zacks Investment Research - 8 months ago

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 8 months ago

TEL AVIV, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has entered into definitive agreements with several institutional investors for th...

GlobeNewsWire - 8 months ago

TEL AVIV, Israel, May 06, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), (the “Company”) today announced new data implicating the potential of its anti-MOSPD2 antibodies for t...

GlobeNewsWire - 8 months ago

Data were published in a peer-review manuscript in Clinical & Experimental Immunology Data were published in a peer-review manuscript in Clinical & Experimental Immunology

GlobeNewsWire - 9 months ago

TEL AVIV, Israel, April 21, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it has been awarded a non-dilutive grant of up to 3.175 million New Israeli Shekels ...

GlobeNewsWire - 9 months ago

TEL AVIV, Israel, April 06, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), announced today that it has reached a milestone event under its collaborative agreement with a world-lea...

GlobeNewsWire - 9 months ago

TEL AVIV, Israel, April 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that following the positive interim analysis in the OVAL study, its Japanese licensee N...

Seeking Alpha - 9 months ago

Vascular Biogenics: A Buy On Promising Cancer Therapy

GlobeNewsWire - 10 months ago

TEL AVIV, Israel, March 26, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced an encouraging outcome of the planned interim analysis in the OVAL study, a double-blind ...

Seeking Alpha - 10 months ago

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -23.08% and -31.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for t...

Zacks Investment Research - 10 months ago

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in VBL.

Seeking Alpha - 1 year ago

Vascular Biogenics Ltd. VBLT) CEO Dror Harats on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 0.00% and -67.08%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for th...

Zacks Investment Research - 1 year ago

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

TEL AVIV, Israel, Nov. 06, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that an investigational new drug (IND) application has received clearance from the U.S. Fo...

Seeking Alpha - 1 year ago

Vascular Biogenics' (VBLT) CEO Dror Harats on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q1 2019 Results - Earnings Call Transcript

About VBLT

Vascular Biogenics, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase 3 clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain c... [Read more...]

Industry
Biotechnology
IPO Date
Oct 1, 2014
CEO
Dror Harats
Employees
38
Stock Exchange
NASDAQ
Ticker Symbol
VBLT
Full Company Profile

Financial Performance

In 2019, VBLT's revenue was $562,000, a decrease of -3.93% compared to the previous year's $585,000. Losses were -$19.46 million, -4.89% less than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for VBLT stock is "Buy." The 12-month stock price forecast is 4.35, which is an increase of 65.40% from the latest price.

Price Target
$4.35
(65.40% upside)
Analyst Consensus: Buy